Sorafenib is an effective therapy for HCV-related hepatocellular carinoma (HCC). HCV viral loads were investigated in a study of 33 patients with HCV-related HCC treated with sorafenib for 6 months. Of the six patients who completed 6 months of full-dose sorafenib no significant difference of HCV viral load from baseline to week 24 was found. HCV viral loads of all patients who received sorafenib and those who had tumour response to the drug showed no differences at any time point. Sorafenib does not seem to have antiviral activity against HCV in patients with HCC.